Tyra Biosciences Q1 net loss $18.2M; cash $382.5M; TYRA-300 on track for 2H24 milestones

Tyra Biosciences, Inc.

2024-Q1 EPS reported -$0.35

Net loss of $18.2M in Q1 2024 vs $11.9M in Q1 2023; R&D expenses $17.2M.
Cash, equivalents, and marketable securities of $382.5M as of March 31, 2024; funding through at least 2026.
Closed $200M private placement in Feb 2024.
TYRA-300 on track for ACH IND submission and initial SURF301 results in 2H24.
Appointed Susan Moran, M.D. and S. Michael Rothenberg, M.D., Ph.D. to board.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Tyra Biosciences, Inc. reported the quarter ended March 31, 2024 results: net income First quarter 2024 net loss was $18.2 million.

Period: the quarter ended March 31, 2024
Net income: First quarter 2024 net loss was $18.2 million
Result: reported results

Exact text from the filing

On May 9, 2024, Tyra Biosciences, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1050 earnings releases filed in the last 30 days. Browse all earnings releases →

Tyra Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-056935

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.